Candriam S.C.A. Sells 2,221 Shares of The Clorox Company $CLX

Key Points

• Candriam S.C.A. sold 2,221 shares of The Clorox Company, reducing its holdings by 14.4% to 13,155 shares, which are valued at approximately $1,937,000.
• Clorox reported an earnings per share (EPS) of $2.87 for the last quarter, exceeding analysts' estimates, and has projected a FY 2026 EPS guidance of 5.950-6.30.
• The company declared an increased quarterly dividend of $1.24 per share, yielding 4.1%, with the payment date set for Friday, August 29th.

Candriam S.C.A. lessened its holdings in shares of The Clorox Company (NYSE:CLX - Free Report) by 14.4% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 13,155 shares of the company's stock after selling 2,221 shares during the quarter. Candriam S.C.A.'s holdings in Clorox were worth $1,937,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. OneDigital Investment Advisors LLC bought a new stake in Clorox in the 1st quarter worth approximately $247,000. Brown Miller Wealth Management LLC bought a new stake in Clorox in the 1st quarter worth approximately $399,000. Roman Butler Fullerton & Co. bought a new stake in Clorox in the 1st quarter worth approximately $400,000. Wedge Capital Management L L P NC increased its stake in Clorox by 33.5% in the 1st quarter. Wedge Capital Management L L P NC now owns 28,510 shares of the company's stock worth $4,198,000 after acquiring an additional 7,159 shares during the last quarter. Finally, Cornerstone Wealth Group LLC increased its stake in Clorox by 19.0% in the 1st quarter. Cornerstone Wealth Group LLC now owns 25,582 shares of the company's stock worth $3,767,000 after acquiring an additional 4,085 shares during the last quarter. Institutional investors own 78.53% of the company's stock.

Clorox Price Performance

CLX opened at $120.1760 on Friday. The business has a fifty day moving average of $124.25 and a 200 day moving average of $135.30. The Clorox Company has a 52-week low of $117.35 and a 52-week high of $171.37. The company has a quick ratio of 0.57, a current ratio of 0.84 and a debt-to-equity ratio of 5.15. The stock has a market cap of $14.70 billion, a P/E ratio of 18.43, a PEG ratio of 0.96 and a beta of 0.49.

Clorox (NYSE:CLX - Get Free Report) last posted its quarterly earnings data on Thursday, July 31st. The company reported $2.87 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.24 by $0.63. Clorox had a return on equity of 377.86% and a net margin of 11.40%.The company had revenue of $1.99 billion during the quarter, compared to analysts' expectations of $1.94 billion. During the same quarter in the previous year, the business earned $1.82 EPS. Clorox's revenue was up 4.5% compared to the same quarter last year. Clorox has set its FY 2026 guidance at 5.950-6.30 EPS. As a group, sell-side analysts anticipate that The Clorox Company will post 7.15 EPS for the current year.

Clorox Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, August 29th. Investors of record on Wednesday, August 13th will be issued a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a yield of 4.1%. The ex-dividend date is Wednesday, August 13th. This is an increase from Clorox's previous quarterly dividend of $1.22. Clorox's dividend payout ratio (DPR) is presently 76.07%.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on the company. JPMorgan Chase & Co. reduced their price objective on Clorox from $144.00 to $140.00 and set a "neutral" rating on the stock in a research note on Friday, July 25th. Jefferies Financial Group reduced their price objective on Clorox from $167.00 to $145.00 and set a "buy" rating on the stock in a research note on Thursday, June 26th. Morgan Stanley dropped their target price on Clorox from $150.00 to $137.00 and set an "equal weight" rating for the company in a report on Friday, August 1st. Wells Fargo & Company lifted their target price on Clorox from $135.00 to $138.00 and gave the stock an "equal weight" rating in a report on Friday, August 1st. Finally, Barclays dropped their target price on Clorox from $129.00 to $119.00 and set an "underweight" rating for the company in a report on Tuesday, July 15th. One research analyst has rated the stock with a Buy rating, eight have given a Hold rating and three have given a Sell rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Reduce" and a consensus price target of $143.36.

Clorox Profile

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.

Want to see what other hedge funds are holding CLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for The Clorox Company (NYSE:CLX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.